Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide

Neoplasma

Volumn 48, Issue 5, 2001, Pages 419-424

  Madarova J ^a   Lukesova M ^a   Hlobilkova A ^a   Rihakova P ^a   Murray, P G ^a   Student V ^a   Vojtesek B ^a   Kolar Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Androgen ablation; Bcl 2 protein family; Cell cycle; Nuclear receptors; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLIN DEPENDENT KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; RETINOID X RECEPTOR;

APOPTOSIS; ARTICLE; GENE CONTROL; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0035210064     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
2. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal human fibroblasts
3. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
4. Prognostic markers in clinically localised cancer
5. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
6. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells
7. Bcl-x, a bcl-2-regulated gene that functions as a dominant regulator of apoptotic cell death
8. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
9. Prognostic significance of Bcl-2 in clinically localized prostate cancer
10. p53 oncogene mutations in the three human prostate cancer cell lines
11. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
12. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer
13. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
14. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
15. Basic science aspects of prostate cancer
16. BRCA1 as a potential human prostate tumor suppressor: Modulation of proliferation, damage responses and expression of cell regulatory proteins
17. ICI 176,334: A novel non-steroidal, peripherally selective antiandrogen
18. Enhanced expression of cyclin-dependent kinase inhibitor in apoptosis of androgen-independent prostatic cancer cell line induced by calcium ionophore
19. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
20. A superfamily of potentially oncogenic hormone receptors
21. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
22. Androgen receptor alterations in prostatic carcinoma
23. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
24. Sample preparation for protein electrophoresis and transfer
25. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours
26. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
27. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
28. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis
29. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
30. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
31. Fluorimetric DNA assay for cell growth estimation
32. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
33. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins
34. Androgen receptor gene expression in human prostate carcinoma cell lines
35. The androgen receptor in prostate cancer
36. From estrogen to androgen receptor: A new pathway for sex hormones in prostate
37. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU-145 cells
38. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention